Press releases
Press releases
23 October 2023: Otrivin Nasal Mist, a new generation of nasal spray, has been launched to bring greater comfort and ease of use to people suffering from nasal congestion due to colds, allergic rhinitis and sinusitis[3]. The new innovation, developed by consumer health company Haleon and Aptar Pharma, uses new microdroplet technology[1] to dispense a full but gentle mist which evenly covers inflamed areas, with no dripping at the back of the nose and throat[2].
The new design is a significant improvement on other pump devices[2][5]. A shorter nozzle means more comfort when using the product, while the one push button ensures ease of application, particularly for people who may have limited movement and strength in their hands[6]. The Otrivin Nasal Mist begins working in as little as 2 minutes after application and lasts for up to 12 hours.[3]
Nasal congestion is one of the main symptoms of colds and flu and affects two-thirds of the world’s population every year[4]. Caused by inflammation of the surfaces in the nose, nasal congestion can also be caused by rhinosinusitis, upper respiratory tract infections and allergic rhinitis.[3]
Fernando Bódalo, Vice-President, Global Brand Lead Respiratory at Haleon, said: “Nasal congestion related to colds, flu and allergic rhinitis is commonplace. Medicated nasal sprays are the most effective way to relieve nasal congestion when used correctly.[3] Yet we know that only half of people use a nasal spray, largely due to discomfort caused by the1 physical sensation and action of current sprays.[4] The good news is that there is a new generation of nasal spray available, using specialist technology that greatly improves comfort in use[5][6].”
Otrivin Nasal Mist is the result of a seven-year collaboration between researchers at Haleon and Aptar Pharma, developing Aptar’s proprietary pump technology (Lateral Control System) and ensuring compatibility with Haleon’s Otrivin formulations. This is the first worldwide launch of a product using the Lateral Control System technology.
Stefan Ritsche, President, Global Market Development, Consumer Health Care Division, Aptar Pharma, said: “Aptar Pharma is proud of our partnership with Haleon in developing this innovative nasal spray technology. Our patented Lateral Control System technology offers consumers an improved delivery experience and will be a real game changer in the decongestant and nasal spray markets.”
How to use NEW Otrivin Nasal Mist[1]:
Otrivin Nasal Mist is available from today in pharmacies across Poland, Greece and Portugal, before being rolled out to other parts of the world.
Ends
+44 (0) 7721376006
About Otrivin
Otrivin is a Haleon brand and a world leader in nasal health, being ranked as the world’s #1 non-prescription nasal decongestant spray in 2022. Otrivin is available in many countries around the world and has a global range of medicated & non-medicated nasal health products available for babies, children and adults that cover needs from nasal congestion to everyday nasal hygiene.
About Haleon
Haleon (LSE / NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon’s product portfolio spans five major categories - Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum - are built on trusted science, innovation and deep human understanding.
For more information, please visit www.haleon.com
About Aptar Pharma
Aptar Pharma is part of AptarGroup, Inc. (NYSE: ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies. Aptar serves a number of attractive end markets including pharmaceutical, beauty, food, beverage, personal care and home care. Using market expertise, proprietary design, engineering and science to create innovative solutions for many of the world’s leading brands, Aptar in turn makes a meaningful difference in the lives, looks, health and homes of millions of patients and consumers around the world. Aptar is headquartered in Crystal Lake, Illinois and has 13,500 dedicated employees in 20 countries.
For more information, visit www.aptar.com
[1] Haleon Data On File: Khone CHRD Finished Product specification.
[4] Respiratory Health Landscape – IPSOS, 5 markets 2022.
[5] Haleon Data on file: Usability Testing Consumer Research: Quantitative, Qualitative and Neuroscientific.
[6] Haleon Data on file: Project Khone Hand Dexterity Qualitative Report.
Related
